Starpharma Holdings Limited
SPHRY · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $5,850 | $8,289 | $4,343 | $5,162 |
| % Growth | -29.4% | 90.9% | -15.9% | – |
| Cost of Goods Sold | $9,579 | $632 | $1,717 | $2,776 |
| Gross Profit | -$3,729 | $7,657 | $1,223 | $1,906 |
| % Margin | -63.7% | 92.4% | 28.1% | 36.9% |
| R&D Expenses | $12,080 | $15,580 | $18,870 | $18,941 |
| G&A Expenses | $3,031 | $3,572 | $3,768 | $3,292 |
| SG&A Expenses | $6,261 | $7,236 | $7,622 | $6,860 |
| Sales & Mktg Exp. | $3,230 | $3,664 | $3,854 | $3,568 |
| Other Operating Expenses | $0 | -$4,412 | -$597 | $0 |
| Operating Expenses | $18,341 | $18,404 | $25,896 | $25,801 |
| Operating Income | -$22,070 | -$10,747 | -$34,508 | -$35,095 |
| % Margin | -377.3% | -129.7% | -794.6% | -679.9% |
| Other Income/Exp. Net | $12,080 | $2,582 | $18,870 | $18,941 |
| Pre-Tax Income | -$9,990 | -$8,165 | -$15,638 | -$16,154 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9,990 | -$8,165 | -$15,638 | -$16,154 |
| % Margin | -170.8% | -98.5% | -360.1% | -312.9% |
| EPS | -0.24 | -0.2 | -0.38 | -0.4 |
| % Growth | -20% | 47.4% | 5% | – |
| EPS Diluted | -0.24 | -0.2 | -0.38 | -0.4 |
| Weighted Avg Shares Out | 41,719 | 40,825 | 40,904 | 40,690 |
| Weighted Avg Shares Out Dil | 41,718 | 41,143 | 40,904 | 40,690 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1,467 | $1,269 | $217 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $267 | $1,115 | $1,193 | $356 |
| EBITDA | -$9,723 | -$9,632 | -$17,042 | -$15,798 |
| % Margin | -166.2% | -116.2% | -392.4% | -306% |